T-Cell Therapy Produced Prolonged Remission in Relapsed Pediatric ALL

TDT/SCD Lentiviral Therapy Boasts Quick, Well-Tolerated Engraftment in Patients

In response to the death, Pfizer is pausing dosing associated with the crossover portion of the phase 3 CIFFREO trial.

First Patient Set to Receive bluebird’s Approved Sickle Cell Gene Therapy, Lyfgenia

KL003 favorably compares to platelet and neutrophil recovery rates of approved gene therapies.

David Jacobsohn, MD, MBA, chief, division of Blood and Marrow Transplantation, Children’s National,

Intellia’s Phase 3 Clinical Trial for CRISPR-Based Gene Therapy Enrolls First Patient

Lovo-cel was approved as Lyfgenia in December 2023.

Prime Medicine’s Gene-Edited Stem Cell Product PM359 Cleared for US Trial in Chronic Granulomatous Disease

The first patient in the trial, which is evaluating NTLA-2001 for the treatment of ATTR Amyloidosis, was enrolled at MedStar Washington Hospital Center.

Jennifer Gori, PhD, vice president of research at Prime Medicine

Advances in CRISPR/Cas9 Gene Editing Will Be Highly Represented in ASGCT Presentations This Year

The company anticipates that initial data from the study will be announced next year.

Terence R. Flotte, MD, the vice president of ASGCT and the provost and executive deputy chancellor of UMass Chan Medical School

May 5th 2024

Patient With DMD Dies in Pfizer’s Phase 2 Gene Therapy Trial

Terence R. Flotte, MD, the vice president of ASGCT, discussed what attendees can expect at the ASGCT Annual Meeting this year.

Related Content

TDT/SCD Lentiviral Therapy Boasts Quick, Well-Tolerated Engraftment in Patients

In response to the death, Pfizer is pausing dosing associated with the crossover portion of the phase 3 CIFFREO trial.

First Patient Set to Receive bluebird’s Approved Sickle Cell Gene Therapy, Lyfgenia

KL003 favorably compares to platelet and neutrophil recovery rates of approved gene therapies.

Intellia’s Phase 3 Clinical Trial for CRISPR-Based Gene Therapy Enrolls First Patient

Lovo-cel was approved as Lyfgenia in December 2023.

Prime Medicine’s Gene-Edited Stem Cell Product PM359 Cleared for US Trial in Chronic Granulomatous Disease

The first patient in the trial, which is evaluating NTLA-2001 for the treatment of ATTR Amyloidosis, was enrolled at MedStar Washington Hospital Center.

Advances in CRISPR/Cas9 Gene Editing Will Be Highly Represented in ASGCT Presentations This Year

The company anticipates that initial data from the study will be announced next year.

May 5th 2024